SMA is a rare, inherited condition that causes progressive muscle weakness, affecting movement, breathing and swallowing. Without treatment, the condition can lead to severe disability and, in its ...

Some of these babies will need to stay in hospital. But our new guidance says babies born after 35 weeks who are on intravenous antibiotics can be switched to a simple liquid oral antibiotic and taken ...

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] ...

All NICE products on stomach cancer. Includes any guidance and quality standards.

There is a commercial access agreement for semaglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043] ...

For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...

NICE today announced the appointment of Dr Adrian Hayter as its new chief medical officer, bolstering the institute’s clinical leadership, following the appointment of CEO Professor Jonathan Benger ...